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Abstract: Understanding the regulation of gene activities depending on DNA methylation 
has been the subject of much recent study. However, although polymorphisms of the 
HTR2A gene have been associated with both obesity and psychiatric disorders, the role of 
HTR2A gene methylation in these illnesses remains uncertain. The aim of this study was to 
evaluate the association of HTR2A gene promoter methylation levels in white blood cells 
(WBC) with obesity traits and depressive symptoms in individuals with metabolic 
syndrome (MetS) enrolled in a behavioural weight loss programme. Analyses were based 
on 41 volunteers (mean age 49 ± 1 year) recruited within the RESMENA study. Depressive 
symptoms (as determined using the Beck Depression Inventory), anthropometric and 
biochemical measurements were analysed at the beginning and after six months of  
weight loss treatment. At baseline, DNA from WBC was isolated and cytosine methylation 
in the HTR2A gene promoter was quantified by a microarray approach. In the whole-study 
sample, a positive association of HTR2A gene methylation with waist circumference and 
insulin levels was detected at baseline. Obesity measures significantly improved after six 
months of dietary treatment, where a lower mean HTR2A gene methylation at baseline was 
associated with major reductions in body weight, BMI and fat mass after the treatment. 
Moreover, mean HTR2A gene methylation at baseline significantly predicted the decrease 
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in depressive symptoms after the weight loss treatment. In conclusion, this study provides 
newer evidence that hypermethylation of the HTR2A gene in WBC at baseline is 
significantly associated with a worse response to a weight-loss intervention and with a 
lower decrease in depressive symptoms after the dietary treatment in subjects with MetS. 
Keywords: DNA methylation; HTR2A gene; obesity; metabolic syndrome; energy 
restriction; depressive symptoms; adiposity; epigenetics 
 
1. Introduction 
Depressive disorders are a significant cause of disability in developed countries and their 
prevalence is expected to increase in the coming years [1]. This psychiatric disease has been suggested 
to be often related to the metabolic syndrome (MetS), a state characterized by a combination of central 
obesity, peripheral insulin resistance, hypertension and serum lipid abnormalities [2,3]. Different 
theories exist concerning the MetS-depression relationship, but most suggest that it is bidirectional and 
mediated by several common mechanisms, such as low-grade inflammation, unhealthy dietary habits 
and genetic factors [4,5]. 
Indeed, lifestyle and genetic factors affect both depression and MetS [6,7]. Moreover, recent studies 
have provided evidence that the pathogenesis of these diseases may be also influenced by epigenetic 
marks [8,9]. In this context, epigenetics is defined as the study of heritable changes in gene expression 
that, unlike polymorphisms, occur without changes in the DNA sequence and are not permanent [6]. 
Therefore, epigenetic mechanisms may be capable of explaining some interactions between genetic 
and environmental factors (e.g., diet, physical activity or drugs), regulating gene expression over the 
entire lifetime of the organism [10]. Epigenetic changes include multiple processes such as covalent 
histone modifications, chromatin folding or microRNA abnormalities or DNA methylation of  
cytosine-phosphate-guanine (CpG) residues, which is probably the issue which has most extensively 
been studied [6,10]. Whole-genome analysis has often shown an inverse association between DNA 
methylation and gene expression, especially in the promoter region [11]. Moreover, DNA methylation 
has been demonstrated to be a predictive tool in the assessment of responses to a nutritional 
intervention [9,12]. 
Serotonin (5-HT) is a monoamine neurotransmitter involved in the regulation of important 
functions such as body temperature, sleep, pain, mood or energy balance [13,14]. Thus, disturbances of 
the serotonergic pathway have been implicated in both MetS and depressive disorders [13]. There are 
multiple 5-HT receptors, each with several subtypes and different biological roles [15]. Among them 
the serotonin 2A receptor, which is encoded by the 5-hydroxytryptamine receptor 2A (HTR2A) gene [16], 
has been involved in the pathogenesis of major psychiatric disorders and obesity [17,18].  
In addition to several single nucleotide polymorphisms (SNPs) that have been reported for the HTR2A 
gene [18], DNA methylation factors have also been implicated in the regulation of HTR2A gene 
expression [19]. However, results have been both diverse and inconclusive [16,20,21]. 
The goal of the present study was to assess the association of HTR2A gene promoter methylation 
levels with obesity measures (e.g., BMI, body weight or fat mass) and depressive symptoms. We tested 
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this hypothesis by determining HTR2A gene promoter methylation levels in white blood cells (WBC) 
of subjects with MetS enrolled in a behavioural weight-loss programme, and then by comparing these 
methylation levels with both baseline and follow-up obesity traits and depressive symptoms. 
2. Materials and Methods 
2.1. Subjects and Study Protocol 
The present research is a secondary analysis of the RESMENA (Metabolic Syndrome Reduction in 
Navarra) project which is a randomized controlled trial, focused on improving MetS features through 
two dietary strategies (the control and the RESMENA diets) designed for weight loss during a  
six-month period [9,22–25]. Both diets were designed following the same energy restriction (−30% of 
the studied requirements), cholesterol (>300 mg/day) and fibre content (20–25 g/day). The control diet 
was based on the American Heart Association (AHA) guidelines, including 3–5 meals/day, a 
macronutrient distribution of 55% total caloric value (TCV) from carbohydrates, 15% proteins and 
30% lipids. On the other hand, the RESMENA diet was designed with a higher meal frequency, 
consisting of 7 meals/day, and a macronutrient distribution of 40% TCV from carbohydrates,  
30% proteins and 30% lipids, as described elsewhere [23]. 
In this analysis within the RESMENA study, 41 Caucasian adults of the two arms of the study were 
pooled [23–26]. The study was approved by the Ethics Committee of the University of Navarra 
(065/2009) and appropriately registered at Clinical Trials.gov; NCT01087086. Each participant 
provided written informed consent for participation in agreement with the Declaration of Helsinki. 
This research was performed following the CONSORT 2010 guidelines. This study was conducted in 
the Metabolic Unit of the University of Navarra in Pamplona, Spain, over a period of 23 months (from 
January 2010 to November 2011) [23]. Details of the design and methods of this trial have been 
reported elsewhere [26]. 
2.2. Anthropometry and Blood Pressure 
Anthropometric measurements were taken with participants in fasting conditions and wearing only 
their underwear and using previously validated procedures [26]. Body mass index (BMI) was 
determined as the body weight divided by the squared height (kg/m2). Systolic (SBP) and diastolic 
(DBP) blood pressures were measured following standardized World Health Organization criteria [27]. 
Body composition was specifically measured by a dual-energy X-ray absorptiometry (DEXA Lunar 
Prodigy, GE Medical Systems, Madison, WI, USA). Anthropometric measurements as well as blood 
pressure determinations were carried out at the beginning and at the end point of the intervention. 
2.3. Biochemical Analysis 
Venous blood samples were taken at baseline and at the end of the study after a 12 h overnight fast 
period by venipuncture. The EDTA–plasma and serum samples as well as WBC were separated from 
whole blood by centrifugation at 3500 rpm, 5 °C, 15 min (Model 5804R, Eppendorf, Germany), and 
were frozen immediately at −80 °C until assay (WBC in buffy-coat with and without Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) as described elsewhere [9,28,29]. 
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Serum glucose, total cholesterol, triglycerides, and non-esterified fatty acids (NEFAs) were 
measured in a Pentra autoanalyser C-200 (HORIBA ABX, Madrid, Spain) with commercially available 
kits. Serum fasting insulin was measured by an enzyme immunoassay kit (Mercodia, Uppsala, Sweden). 
2.4. Psychological Assessment 
Symptoms of depression were assessed at the beginning and at the end of the study using the 
validated Spanish version of the Beck Depression Inventory (BDI) as published elsewhere [30].  
The BDI is a 21-item test that measures the presence and degree of depressive symptoms in 
respondents. Scores can range from 0 to 63, with a score of 10 or higher indicating moderate 
depressive symptoms. Question number 19 of the test, relating to weight loss, was discarded from all 
the analyses given that losing weight is considered a manifestation of depression. However, in our 
volunteers, it was considered a positive aspect because they were enrolled in a weight loss  
treatment programme [23]. 
2.5. DNA Isolation and DNA Methylation Study 
Genomic DNA from WBC was obtained using the Master Pure kit (Epicenter, Madison, WI, USA), 
and its quality was assessed with PicoGreen dsDNA Quantitation Reagent (Invitrogen, Carlsbad, CA, 
USA). A total of 500 ng of DNA were modified using EZ-96 DNA Methylation Kit (Zymo Research 
Corporation, Orange, CA, UDA) according to the manufacturer’s instructions, thus converting cytosine 
into uracil. 
Array-based specific DNA methylation analysis was performed with the Infinium Human 
Methylation 450K bead chip technology (Illumina, San Diego, CA, USA). Bisulfite-treated genomic 
DNA was whole-genome amplified, hybridized to HumanMethylation450 BeadChips (Illumina, San 
Diego, CA, USA) and scanned using the Illumina iScanSQ platform. The intensity of the images was 
extracted with the GenomeStudio Methylation Software Module (version 1.9.0, Illumina, San Diego, 
CA, USA). β-Values were computed using the formula β-value = M/(U + M) where M and U are the 
raw “methylated” and “unmethylated” signals, respectively. β-Values were corrected for type I and 
type II bias using the peak-based correction. The data were normalized in R using a categorical Subset 
Quantile Normalization method (SQN) and probes associated to X and Y chromosomes were filtered 
out using the pipeline developed by Touleimat and Tost [31]. Probes containing SNPs with a minor 
allele frequency (MAF) >0.001 in Iberian population in Spain were removed from the analysis. The 
methylation status of 20 CpG sites of the HTR2A gene that codes for the HTR2A receptor were 
selected from the Illumina array and analysed separately. Specific CpG sites located in the 
transcriptional regulatory region (promoter, 5′-untranslated region and exon 1) were included  
(Figure 1). Reference names and characteristics of the selected CpG were reported (Table 1). 
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Figure 1. Genomic localization and nucleotide sequence of the 20 CpGs sites covered by 
the Illumina array for the study of DNA methylation levels of 5-hydroxytryptamine 
(serotonin) receptor 2A promoter (from −2188 to +10 pb). Transcription Start Site (TSS). 
Putative consensus sequences for nine transcriptional factors (AHRR: AHR-related factors, 
HIF: Hypoxia inducible factor, CREB: cAMP-responsive element binding proteins, HESF: 
Vertebrate homologs of enhancer of split complex (Basic helix-loop-helix domain 
containing, class B, 2 (secondary DNA binding preference)), NRSF: Neuron-restrictive 
silencer factor, XCPE: X gene core promoter element 1, E2FF: E2F transcription factor 6, 
ZF57: KRAB domain zinc finger protein 57, DMTE: Drosophila motif ten element), found 
with MatInspector. 
 
Table 1. Information of the selected CpG sites for HTR2A gene. 
CpG ID 1 Illumina ID CHR Position 2 Reference 3 
1 cg15894389 13:47470857 c.-688 
2 cg02250787 13:47470989 c.-820 
3 cg06476131 13:47471052 c.-883 
4 cg16188532 13:47471090 c.-921 
5 cg09361691 13:47471169 c.-1000 
6 cg11514288 13:47471197 c.-1028 
7 cg27068143 13:47471264 c.-1095 
8 cg10323433 13:47471562 c.-1393 
9 cg02027079 13:47471705 c.-1536 
10 cg01192538 13:47472050 c.-1881 
11 cg01620540 13:47472064 c.-1895 
12 cg06020661 13:47472138 c.-1969 
13 cg09798090 13:47472140 c.-1971 
14 cg24320398 13:47472158 c.-1989 
Chrmosome 13, GRCh37 Genome Assembly, release 71 
Exon 1 Exon 2 
TSS 
HTR2A (NM_001165947.2) 
47472360 
CGCTGCCTGCTCGCCAGCGTGCATATTTAACGTGGAGGGGTAGGAGGGTGGCAGGCATGGCAGTGAGGGGGGCACTAAGGCACCCACCCAGGAAATAGGTGGCTAGATCTCGA
CCACAGGGTGCCAGCTGCAGGCTGCAGGAGAGGACATGTGAGAAACACGCATACAGAGGTAGCACcgGAGAcgAAGTGGGATCTGGCAGCGAGAATGAAGGAAGAGTCGCGGA
TAACAGCAGCTGTCTGAAGAGGTGGTGATTCCATCATGCAAGCCAATGGGTAGGAACAAGCACTGAGAGCCGGGCAGGGGGATGCGGAGTGAGGGAAGATGCTGAGGTCAAGGT
CTCCCAGGCTACCATGGAAGGAGCCAATGGGCAGCTAGAGATTTAGGTCTGGAACTGAGAGAAATAATCAGCTATGAAGGTACAGACTTGGCCACAAACATATTGAAGGCATGAGA
GTGGTTGAATTTGTCCAGGGAGAATGTGAAGAACAGAAGGTGATAGAACTGTAGCAAAACCCAACTATTGAGGAAAATATTTTCATGCCTGCAAAAAGAGAGAGATcgAACTGCCTC
CTTTAGAAACCTACTTGGGAAAGGGCTTTCTTTACAAGTAAGGCAAGTTGTCATTACTGGTGGGGGAAAAAAATTGGTACTGCGAAACCAACTTATTTCCTACCACATGTGAGGTTTT
GAATAATATCTGGGTGGCATATTTCTGCTGAAGAAAATAAGCCAGTTCAATGGTGTATCTATTAAATAAAAATAGTGCTAATAGTTTATCAGAGTTATCACCACAGACGTGCCTAGCC
ACCCTGAGCCTATGTGGCCAATGTCAGTAATTCCACTCTGGACACAAACACTGTTGGCTTTGGATGGAAGTGCcgGACACTCACAGCACTCcgAGGACATACTGTTTTCTAGCCTTATTT
ATGTTCTCTCTTCACCCTTCAGCCTAAAAAATTACCACAGTGCCACTTACCTACCTTAATGGGAATCTGCACAAAAGGCCATTTCTCCAGTTTCTCTCAAAAGCAAAGGAAAACTTCCCA
ATATTAATATGTAGCAAAAAGAGGGAGAAGAAAAAGCCTGTTTGGTCCGCCCTCCTGGCTGTTGCTACCTTGCAGCTTATGACATACACATAGAGGGAGGTCTGATGAAATGAACG
AGACAGTCAGAGAGCTACTCCATTCCCGTGGAAACCAGGAGTCCCTTGGTGCAGACAGCTCTTCCTACTTTCCCATGCAGTTCTTTTGTGcgACTTTGAGGGGCTCGTGAATGATTTCT
AAATGTGTGCCTGCTGAGGcgAGCCGCACAGGGAGGGAGGAACCCAGCcgAGCcgTGCCAGAGGAAGCCAACAGGATCCTAGCAGTGCGGGAGCTGGCTCAGCTCTTGCATGCAGT
TTTTGAAGTCAGCAAAACAGAAACCAAATTACTATCATATTATGCTGGTGGAAGATCAAGAAGAGGGGACTCTACACCAGTTTAATTACTGTGAGAGATGCAGCGAGTCACAGAATA
ACAAATGTATCTCATGTGTGGACCCTGAAGACAAATGTAAGTTCTCATGCcgCTATATTTTATTGCTGTGTAATTTTCTTTCcgGTTTGAAATCATGCTTGGCCAACATGTAATCATTTCAA
TGAGAATTTCCAGGGAGGAAAGTTGTCTGCTAATCTTTACTTAAGACTTTTTTGTTTTCCTTTTATTAGCTAAGCAACATTATAGGAGCTGAAATTCCTGACAGCAGCTGTGGCAATTCA
GCTTAAGAATGGCTGAGAACTGTAACCCAAAGTACATCCAATTACTATGGGATTAACACTGGATGTATTTTTAATTGACTTTCTTAATGTAGAATGTGTACATCCCCACTGTTTCTGATT
GCATGCTATTTTAATAATACTGTTGCTAAACTAGTACCATcgGCATAACCAACAAAATGAGATATAGTTAAACAAGAGTCCCAGTAGTTATAAAACTTTTCTTCTTTGTCCAGGACATTTA
TCTTCCcgAGcgCTCAAAAAAAACCCTGCAACCTCTATGCTAAAAGTTCATTCTGCTTTTTTGTCCTcgGTTTGGTGAGAAAATAATAAAACCAAACAGTGGACTCTCCTAAAATTGTGAA
TGAAGAAAACTTACAGCCACCACAGTTCAGTTCTTTAACTATCATTGTAATAATGGAAGACAAAAATCCAGCCCcgG 
2
45
TSS 
Exon 3 
AHRR 
20 19 18 17 
13-12 15 
16 
14 
11 10 
9 
8 
7 6
3 1XCPE - E2FF 
HESF 
CREB-HIF 
NRSF 
HIF/CREB/HESF 
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Table 1. Cont. 
15 cg18200810 13:47472200 c.-2031 
16 cg15692052 13:47472250 c.-2081 
17 cg24118521 13:47472330 c.-2161 
18 cg23881368 13:47472343 c.-2174 
19 cg05506829 13:47472349 c.-2180 
20 cg07075299 13:47472360 c.-2191 
1 Studied CpG identifier; 2 Genome assembly: GRCh37, Ensemble release 73.37; 3 It begins in the first 
nucleotide of exon 1. 
2.6. Analysis of Gene Expression by Quantitative Real-Time PCR 
Total RNA from WBC was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. The integrity of isolated RNA was also evaluated by 
Experion (BioRad, Hercules, CA, USA), following the manufacturer’s instructions. Briefly, denatured 
RNA samples (1 μL) were mixed with sample buffer provided, and 6 μL of each mixed sample was 
loaded in RNA StdSens chips (Bio-Rad) for analysis. In all samples, we also evaluated the RNA 
quality indicator number (RQI) and this was considered as optimal (ranging from 7.9 to 10). 
Furthermore, HTR2A transcript expression levels were assessed using quantitative real-time RT-PCR 
(qPCR). cDNA was synthesized from total RNA (1 μg) of the entire cohort individuals using High 
Capacity cDNA Reverse Transcription Kit with RNase Inhibitor following the manufacturer’s 
instructions (Life Technologies, Foster city, CA, USA). The transcript levels for HTR2A gene and one 
housekeeper gene were measured using an ABI Prism 7900HT Fast Real-Time PCR system with a 
384-well format and TaqMan Gene Expression Assays (Life Technologies, Foster city, CA, USA) 
(HTR2A: Hs01033524_m1 and GAPDH: Hs02758991_g1). The ΔΔCT method was used for 
quantification (ABI) and the fold changes are reported as 2−ΔΔCT [32]. 
2.7. In Silico Sequence Analysis 
Human genomic DNA sequences, from 2188 bp upstream to +1 pb of the transcription Start Site 
(TSS) of the HTR2A gene, were downloaded from the NCBI database (GenBank: NG_013011.1, 
13:47472360-13: 47469640) [33]. Possible transcription factor-binding sites were predicted on genomic 
DNA sequences using MatInspector software (Genomatix Software GmbH, Munich, Germany), which is 
a specifically designed tool for promoter analysis [34]. 
2.8. Statistical Analyses 
Results are shown as mean ± SEM. Data normality was determined by the Shapiro-Wilk test.  
The mean methylation value of the HTR2A gene promoter region, including the 20 CpGs, was 
calculated. Baseline characteristics of participants according to tertiles of mean HTR2A gene 
methylation were compared. Means and SEM for each variable across the HTR2A gene methylation 
tertiles were calculated, with the differences among them assessed using one-way analysis of variance. 
Pearson correlations were fitted to evaluate the potential correlations of HTR2A transcriptional 
regulatory region methylation with all sites across the promoter region, gene expression and changes in 
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anthropometric measurements and depressive symptoms. Body weight, WC, BMI and fat mass were 
divided by medians and the differences between groups were analysed using a Student’s t-test. 
Moreover, multiple testing correction (Benjamini–Hochberg) analyses were performed when 
appropriate. Statistical analyses were performed using STATA version 12.0 (StataCorp., College 
Station, TX, USA). p-Value < 0.05 was considered as statistically significant. 
3. Results 
The CpG sites were located within the HTR2A promoter region, a 2198 bp region positioned  
from −2188 to +10 (Figure 1). The transcription factor binding sites in the activation regions of the 
HTR2A promoter were screened by using MatInspector. These analyses showed that the promoter 
region contained a consensus binding motif in the studied CpG sites for seven transcription factors 
(AHRR, HIF, CREB, HESF, NRSF, XCPE, E2FF) (see Figure 1 and supplementary data S1). Mean 
DNA methylation levels revealed a high correlation with some of the CpG sites for the HTR2A gene 
(supplementary data S2). Moreover, DNA methylation levels of CpG sites within the promoter region 
were associated in some different regions. These distinct areas might imply the presence of specific 
response elements of gene regulatory machinery in the gene promoter. 
The baseline anthropometric, biochemical and psychological characteristics of the whole-study 
sample (n = 41) stratified by tertiles of baseline mean HTR2A gene promoter methylation levels are 
presented (Table 2). In this context, those individuals in the upper category of mean HTR2A 
methylation levels had a higher waist circumference (WC) and insulin levels. Nevertheless, no 
association between HTR2A methylation levels and depressive symptoms was observed at the 
beginning of the study. 
Table 2. Anthropometric, biochemical and psychological characteristics of the whole-study 
sample stratified by tertiles of mean HTR2A methylation levels at baseline. 
Variables 
Mean HTR2A Gene Methylation % 
p Trend 
Low (n = 14) Medium (n = 14) High (n = 13) 
Body weight (kg) 97.6 ± 4.6 106.4 ± 4.6 110.7 ± 4.8 0.059 
BMI (kg/m2) 37.0 ± 1.0 37.0 ± 1.0 37.0 ± 1.0 0.995 
Waist circumference (cm) 110.8 ± 3.0 114.0 ± 3.0 120.5 ± 3.1 0.027 
Total fat mass (kg) 43.8 ± 2.4 45.9 ± 2.4 45.4 ± 2.5 0.682 
Truncal fat mass (kg) 26.1 ± 1.8 27.6 ± 1.8 26.2 ± 1.9 0.993 
SBP (mmHg) 150.3 ± 4.8 151.2 ± 4.8 148.1 ± 4.9 0.733 
DBP (mmHg) 85.4 ± 2.2 87.3 ± 2.2 84.8 ± 2.3 0.784 
Glucose (mg/dL) 9.8 ± 1.5 7.4 ± 1.5 11.1 ± 1.6 0.498 
Insulin (μU/mL) 11.0 ± 2.3 18.1 ± 2.3 21.7 ± 2.4 0.004 
TC (mg/dL) 225.1 ± 12.4 211.1 ± 12.9 205.1 ± 12.9 0.280 
Triglycerides (mg/dL) 166.8 ± 29.9 224.6 ± 31.1 247.3 ± 31.1 0.079 
NEFA (nmol/L) 0.58 ± 0.05 0.50 ± 0.05 0.56 ± 0.05 0.705 
BDI score 9.8 ± 1.9 8.3 ± 1.9 10.9 ± 1.9 0.636 
Data expressed as mean ± SEM. Bold numbers indicate statistical significance (P < 0.05). Abbreviations: BDI, Beck 
Depression Inventory; BMI, body mass index; DBP, diastolic blood pressure; HTR2A, 5-hydroxytryptamine receptor 2A; 
NEFA, non-esterified fatty acids; SBP, systolic blood pressure; STAI, State Trait Anxiety Inventory; TC, total 
cholesterol. Low ≤ 0.556; Medium = 0.557–0.585; High ≥ 0.587. 
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The 20 selected CpG methylation sites of the HTR2A gene showed few associations with baseline 
body weight, WC, BMI and fat mass (supplementary data S3). After the six-month weight-loss 
treatment, body weight, WC, BMI, fat mass and depressive symptoms significantly decreased in all 
subjects (Figure 2). Changes in body weight, WC, BMI and fat mass were divided by medians 
showing that those participants with a greater response to the dietary treatment had lower HTR2A gene 
promoter methylation levels (Figure 3). Moreover, Pearson correlation analyses between mean HTR2A 
gene methylation levels and changes in anthropometric parameters confirmed these findings, since 
positive correlations between mean HTR2A gene methylation levels and changes in body weight, BMI 
and fat mass, though not in WC, were found. 
Figure 2. Anthropometric, body composition measurements and in depressive symptoms 
in the whole-study sample before and after the dietary treatment n = 32–34. Data are 
expressed as mean (CI 95%). Abbreviations: BDI, Beck depression inventory; BMI, body 
mass index; WC, waist circumference. * p < 0.05. ** p < 0.001. 
 
Figure 3. Association of baseline mean HTR2A gene methylation (%) with changes  
(six-month baseline) in anthropometric and body composition measurements divided by 
their medians in the whole-study sample n = 34. Δ = six-month baseline. Data are 
expressed as mean (CI 95%). Abbreviations: BMI, body mass index; WC, waist 
circumference. <P50 = high responders; >P50 = low responders to the dietary treatment.  
* p < 0.05. 
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Pearson correlation analyses were performed to assess the relationship between baseline HTR2A 
gene methylation levels and changes in body weight, WC, BMI and fat mass after the six-month 
dietary treatment. The analysis of the 20 selected CpG methylation sites of the HTR2A gene showed 
that CpG 4, CpG 7 and CpG 17 sites were also positively related to changes in body weight, BMI and 
fat mass (Table 3). However, after applying a multiple comparison correction, the statistical 
significance was attenuated. In addition, no association between HTR2A gene methylation with 
changes in insulin and triglyceride levels was observed. 
Table 3. Pearson correlation analyses between changes (six-month baseline) in body 
weight, BMI and fat mass with the baseline methylation (%) of HTR2A gene. 
 Δ Body Weight Δ WC Δ BMI Δ Fat Mass (kg) 
Baseline 
CpG 
Sites 
r 
Uncorrected p-
Value 
r 
Uncorrected p-
Value 
r 
Uncorrected p-
Value 
r 
Uncorrected 
p-Value 
cg15894389 1 0.110 0.537 −0.117 0.510 0.127 0.474 0.167 0.346 
cg02250787 2 −0.063 0.725 −0.083 0.639 −0.063 0.723 0.008 0.963 
cg06476131 3 0.284 0.103 0.080 0.652 0.286 0.100 0.381 0.026 * 
cg16188532 4 0.379 0.027 * 0.124 0.483 0.383 0.025 * 0.415 0.015 * 
cg09361691 5 −0.195 0.268 −0.188 0.287 −0.198 0.261 −0.153 0.386 
cg11514288 6 −0.143 0.418 −0.154 0.383 −0.144 0.414 −0.145 0.412 
cg27068143 7 0.369 0.032 * 0.116 0.513 0.397 0.020 * 0.382 0.025 * 
cg10323433 8 0.292 0.094 0.052 0.769 0.350 0.042 0.249 0.155 
cg02027079 9 0.011 0.951 0.160 0.365 0.009 0.957 0.042 0.815 
cg01192538 10 0.225 0.201 0.193 0.274 0.230 0.190 0.214 0.225 
cg01620540 11 −0.070 0.694 −0.251 0.152 −0.014 0.937 −0.073 0.680 
cg06020661 12 0.177 0.316 0.206 0.243 0.196 0.267 0.196 0.267 
cg09798090 13 −0.042 0.814 −0.054 0.762 −0.037 0.837 −0.059 0.740 
cg24320398 14 0.338 0.051 0.266 0.128 0.377 0.028 * 0.343 0.047 
cg18200810 15 0.310 0.075 0.222 0.206 0.360 0.037 * 0.322 0.063 
cg15692052 16 0.091 0.608 −0.025 0.890 0.121 0.494 0.103 0.563 
cg24118521 17 0.342 0.047 0.280 0.108 0.381 0.026 * 0.414 0.015 * 
cg23881368 18 0.297 0.087 0.269 0.124 0.319 0.066 0.291 0.095 
cg05506829 19 0.280 0.108 0.252 0.151 0.297 0.088 0.268 0.125 
cg07075299 20 0.296 0.089 0.250 0.153 0.307 0.078 0.301 0.084 
Data are shown as r and p values from Pearson correlations analysis. Δ = 6-month baseline. Abbreviations: BMI, body mass index; 
HTR2A; 5-hydroxytryptamine receptor 2A; WC, waist circumference. * p-Value < 0.05 after correcting for Benjamini–Hochberg  
multiple comparisons. 
Interestingly, higher methylation levels of both the HTR2A gene promoter and HTR2A CpG17 site 
at baseline were related to a less marked decrease in depressive symptoms after the nutritional 
intervention (Figure 4). 
The gene expression analysis showed very low concentrations in WBC and only revealed values for 
20 participants. No association was found between gene expression and the HTR2A gene promoter 
methylation levels (r = −0.257, p = 0.274), or the methylation of HTR2A CpG 17 site (r = 0.094,  
p = 0.693). 
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Figure 4. Association of the decrease (six-month baseline) in depressive symptoms with 
baseline (A) mean HTR2A methylation; (B) methylation levels of HTR2A CpG17 site; in 
the whole-study sample n = 32. Change = six-month baseline. Abbreviations: HTR2A;  
5-hydroxytryptamine receptor 2A. 
 
(A) 
 
(B) 
4. Discussion 
This study showed a positive association between baseline methylation levels of the HTR2A gene 
in peripheral WBC and both initial and subsequent changes in anthropometric variables, suggesting a 
regulatory action of this gene on methylation levels in the improvement of obesity measures (e.g., 
body weight). Moreover, the baseline methylation levels of the HTR2A gene promoter region were 
associated with a decrease in depressive manifestations after the weight loss treatment. 
In order to detect putative consensus transcription factor binding sites in the entire HTR2A coding 
region, a computer analysis of this region using MatInspector was carried out [34]. This analysis 
showed that the HTR2A CpG 17 site matches a core-binding motif for CREB, HESF and HIF.  
A growing literature has related environmental factors to serotonin release acting on diverse serotonin 
receptors, by the mediation of CREB, which may activate the expression of many genes to produce 
different proteins involved in neural growth, synapse formation, and long-lasting structural changes, 
which may be related to depression [20,21]. As for the HESF transcription factor, it has been involved 
in neuronal excitability in the brain [35]. Moreover, HIF is a key regulator of oxygen homeostasis  
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and has been reported to play a role in the transcriptional regulation of low-grade inflammation,  
tissue-protective signaling pathways or weight loss [36,37]. Since it has been proposed that low-grade 
inflammation promotes both obesity and depression [4], it might be hypothesised that methylation of 
HTR2A could interact with obesity and depressive disorders by hindering the binding of HIF, HESF 
and CREB to the HTR2A gene promoter region. 
Interestingly, the CpG methylation of a promoter region may be a mechanism implicated in gene 
inactivation by blocking its transcription [38]. Nonetheless, in this study, we failed to find an 
association between promoter methylation levels and gene expression, although this might be due to 
the fact that not all samples could be read. One factor that might explain this unexpected finding is that 
the promoter region CpG 17 site, an important transcription factor binding site of HTR2A gene, was 
highly methylated and may have caused a very low HTR2A gene expression in our sample. Moreover, 
other studies have found that DNA methylation is involved in the regulation of HTR2A expression [19].  
On the other hand, a previous study has reported very low concentrations of HTR2A gene expression in 
peripheral blood mononuclear cells, and also an increase of HTR2A gene expression after clinical 
improvement of depressive symptoms [39]. Indeed, this research proposed HTR2A gene as a potential 
biomarker for clinical improvement of depression. 
Diet is considered an important environmental factor that affects DNA methylation [6,28]. In this 
sense, the dietary levels of methyl-donor precursors (vitamins of the B complex or certain amino acids) 
have been shown to be important in the prevention of psychiatric diseases and obesity [40,41]. In this 
context, a balance of DNA methylation levels is important for the correct functioning of the central 
nervous system [40]. Moreover, DNA methylation changes in peripheral WBC have been proposed as 
a useful biomarker for different diseases [13,38]. 
On the other hand, one of the most widely studied SNPs of the HTR2A gene is rs6311 (−1438G > A), 
which has been related to many diseases and conditions such as schizophrenia, alcohol dependence, 
diabetes and obesity [42,43]. For example, it has been suggested that this SNP influences glucose 
homeostasis [42] and also obesity traits (BMI and abdominal obesity) in obese subjects [44]. In the 
present study, we found that hypermethylation of the HTR2A gene was associated with higher baseline 
WC and insulin levels. Interestingly, those subjects with higher methylation of HTR2A gene and also 
the HTR2A CpG 17 site, showed a less marked decrease in body weight, BMI and fat mass after the 
six-month dietary treatment. No previous study has analysed DNA methylation levels of HTR2A gene 
in a population with metabolic syndrome enrolled in a weight loss treatment. These results therefore 
could not be compared. On the other hand, SNPs have not been genotyped in this study. Hence, if the 
methylation levels are tagging a SNP, this may explain why DNA methylation was not associated with 
gene expression, as this SNP influences translation efficiency [20,21]. 
In addition, the HTR2A gene has been directly associated with major depressive disorder [45]. 
Some studies have reported that HTR2A expression is decreased in the brain of patients with 
schizophrenia and in those who have committed suicide [21,46,47]. Moreover, antipsychotic treatment 
has been linked with lower DNA methylation and increased expression of the HTR2A gene [21]. 
Unfortunately, methylation of cytosines of the HTR2A promoter gene in major depressive disorders 
has not been sufficiently investigated to date [16]. In this sense, it might be suggested that the average 
methylation of both the HTR2A gene and HTR2A CpG 17 site predicted the decrease in  
depressive symptoms. 
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Under the assumption of an inverse association between DNA methylation and gene expression [38], 
the density of 5-HT2A receptors might mirror, in part, HTR2A methylation. In this sense, lower density 
of platelet 5-HT2A receptors has been observed in adolescents with eating disorders [48]. Moreover, 
progressive reductions of brain 5-HT2A receptor density have been proposed as an indicator of 
schizophrenia [47]. In contrast, results from animal models found that higher 5-HT2A receptor gene 
expression was linked to obesity [49] and also elevated 5-HT2A receptors in frontal cortex specimens 
were observed in depressed subjects [50]. Hence, the involvement of 5-HT2A receptors in depressive 
disorders remains to be elucidated. 
Some limitations of the study should be mentioned. Firstly, since the sample size is not very large, 
the risk of type II errors (failing to detect real differences) was high. Type II errors are frequent when 
adjustments are used in conjunction with a small effect or a small sample [51]. Therefore, with the aim 
of avoiding type II errors, no covariates were included in the analysis carried out in this study.  
Our approach is consistent with previous investigations that reported that when it is important to 
discover new facts, as is our case, we may be willing to accept more type I errors in order to avoid type 
II errors [52,53]. Hence, in this study, the probability of type II errors is low because important 
statistical differences were found despite the small sample size. However, further studies with a large 
sample size are clearly needed to verify our findings. Secondly, HTR2A methylation levels were not 
measured at the end of the intervention and so it is not possible to confirm whether the dietary 
treatment had an effect on HTR2A gene methylation levels. Thirdly, we failed to find an association 
between promoter methylation levels and gene expression in WBC. Gene expression varies depending 
on the tissue or cell type [54], and it is possible that HTR2A gene is not widely expressed in WBC. 
Moreover, other studies have found that DNA methylation is involved in the regulation of HTR2A 
expression [19]. In addition, validation of these results with other reliable standards such as 
pyrosequencing or bisulfite sequencing might be considered in future studies. 
On the other hand, the strengths of this study are: its novelty; the techniques used for DNA 
methylation quantification, which are known to be the gold standard for epigenetic studies; and its 
relevance for future dietary intervention trials. 
5. Conclusions 
In summary, this study provides novel evidence that hypermethylation of the HTR2A gene in WBC 
at baseline is significantly associated with a worse response to a weight-loss intervention and a less 
marked decrease in depressive symptoms in subjects with MetS. These results, if confirmed, would 
suggest that HTR2A gene methylation in WBC could serve as a useful biomarker to predict weight loss 
and improvement of depressive symptoms after an energy-restricted dietary treatment. However, 
replication in a larger cohort is warranted in order to confirm these findings and to better understand 
the possible biological mechanisms explaining these associations. 
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